- Company
- Sanofi's multiple myeloma tx Sarclisa was approved in Korea
- by Dec 4, 2020 05:53am
- Sanofi-Aventis Korea (CEO Kyung-Eun Bae) announced on the 2nd that its relapsed and refractory multiple myeloma treatment Sarclisa (Isatuximab-irfc) was approval from the MFDS on the 1st. Sarclisa was previously approved as a combination therapy with Pomalidomide and Dexamethasone in patients with multiple myeloma who received more than on
- Company
- Joint venture Akijen withdrew in 6 years
- by An, Kyung-Jin Dec 4, 2020 05:53am
- Akijen, a joint venture established by Samsung Biologics and multinational pharmaceutical company AstraZeneca, is going through the process of rearranging the business in six years. According to Samsung Biologics' quarterly report submitted to the Financial Supervisory Service on the 2nd, the company decided to stop research and developme
- Company
- Rob Kempton inaugurated as the new president of GSK
- by Dec 3, 2020 11:32am
- GSK announced on the 30th that it will appoint Rob Kempton as the president of GSK's Korean subsidiary on Dec 1st. New president Rob Kempton is a healthcare professional with over 20 years of pharmaceutical experience in the US, UK and Asia. After joining GSK in 2013, he was in charge of sales management in the United States of Viiv Health
- Company
- Celltrion completes acquisition of Takeda APAC products
- by An, Kyung-Jin Dec 3, 2020 06:00am
- On Dec. 1, Celltrion announced it completed the acquisition for the Asia-Pacific market products from a multinational pharmaceutical company Takeda Pharmaceutical Company (“Takeda”). In last June, the South Korean company signed a deal to take over the rights to Takeda’s 18 Primary Care product assets from the Asia-Pacific markets for
- Company
- Sanofi cut from Innovative Company list first time in 6 year
- by Eo, Yun-Ho Dec 2, 2020 06:06am
- A multinational pharmaceutical company Sanofi-Aventis Korea has been cut from the list of Innovative Pharmaceutical Companies for the first time in six years. South Korea’s Ministry of Health and Welfare (MOHW, Minister Park Neung-hoo) convened a second Pharmaceutical Industry Fostering and Support Committee meeting for the year and fin
- Company
- Hanmi's Xoterna wins first trial in patent dispute
- by Kim, Jin-Gu Dec 2, 2020 06:06am
- Hanmi won the patent dispute between Hanmi and Novartis over Xoterna (Indacaterol/Glycopyrronium), a treatment for COPD (chronic obstructive pulmonary disease). The Intellectual Property Trial and Appeal Board recently issued a trial decision for partial approval and dismissal in a trial for invalidation of a patent for the Xoterna partia
- Company
- The sales of Dupixent tripled in a year
- by Kim, Jin-Gu Dec 2, 2020 06:06am
- Sales of Dupixent (Dupilumab), a treatment for severe atopic dermatitis, are increasing. Sales have increased since it was applied to health insurance benefits in January of this year. It posted a cumulative sales of &8361;15.6 billion in the third quarter, and is expected to exceed &8361;20 billion by the end of the year. According to I
- Company
- Talzenna didn’t pass the Cancer Assessment Committee
- by Eo, Yun-Ho Dec 1, 2020 06:15am
- The government is conservative about breast cancer-related insurance benefits for PARP inhibitors. According to related industries, Pfizer's Talzenna (Talazoparib) was submitted to the HIRA's Cancer Assessment Committee held on the 25th, but failed. As the range of indications for breast cancer of PARP (poly ADP ribose polymerase) inhibito
- Company
- Lynparza, a big change in the tx of BRCA-mutated cancer
- by Dec 1, 2020 06:15am
- "Most ovarian cancers are found in the 3rd to 4th stage because there is no subjective symptoms. After the first treatment, 70% recur within 3 years, and the 5-year survival rate is only 38%. Maintained by the release of Lynparza. The prognosis of patients is greatly improved through therapy. In particular, the first published 5-year follow-up r
- Company
- Whanin ends sales of Sandoz antidepressants
- by Dec 1, 2020 06:15am
- Sandoz's supply of four antidepressants, which Whanin supplied, will end this year. According to the drug distribution industry on the 27th, Whanin announced that the supply of four Sandoz antidepressants will be suspended as the contract with Sandoz ends on the 30th. The items are ▲Sandoz Escitalopram 5·10·15mg ▲Paroxetine 20mg ▲S
